Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future.

To view this week’s program, visit www.MoneyTV.net

In the interview, Greg Lambrecht, chief executive officer of Singlepoint, reflected on Tuesday’s polling results, particularly as they relate to the legalization of recreational and medicinal marijuana in states across the country. In total, four states – including California, Maine, Massachusetts and Nevada – voted to legalize marijuana for recreational use, bringing the nationwide total to eight states, in addition to the District of Columbia. Additionally, four states voted to legalize or expand the availability of medicinal marijuana. With this vote, a nationwide majority of 28 states and Washington, D.C. have now legalized cannabis for medicinal purposes.

“As more and more states pass not only recreational but medical marijuana, there’s going to be more and more pressure on the legislators and also the administration to allow them to have bank accounts which, in turn, will allow us to put in our credit card merchant processing and let customers pay with their credit cards for cannabis,” Lambrecht stated in the interview.

This result is big news for Singlepoint, as the company recently awakened its SingleSeed subsidiary from a quiet period in order to actively engage the roughly $6 billion industry. Though banks and credit unions across the country have been extremely reluctant to open accounts for dispensaries and other companies operating in the burgeoning cannabis industry, SingleSeed already has experience servicing this market. Lambrecht alluded to this experience in the interview.

“We already spent the time and money of understanding this business and we’re in hundreds of accounts allowing people to use their debit cards, and the banks shut it down. As this gets back opened up, we’re really ready to go,” he continued. “In fact, we’re going to be putting on our SingleSeed.com website a sign-up now for dispensaries to kind of get in line and put their name and information down. That way, when it opens up, we can call them immediately and get them started.”

There’s little doubt that change is coming in the domestic cannabis industry, even as the drug remains illegal at the federal level. To date, about 266 depository institutions nationwide have begun serving marijuana-related businesses, and the U.S. Treasury Department’s 2014 decision to green light banks to offer their services to the industry, as long as any suspicious activity is reported to federal authorities, will likely play a role in continued growth in the financial sector moving forward. This hypothesis played a role in Arcview Research’s projection that the combined domestic medicinal and recreational marijuana markets will climb to a valuation of $22 billion by 2020.

With Singlepoint’s renewed interest in the sector, Lambrecht finished off the MoneyTV interview by announcing plans to attend the 5th Annual Marijuana Business Conference & Expo® in Las Vegas, which begins on November 15. According to Lambrecht, he intends to discuss possible acquisitions within the space, as well as to present the benefits of SingleSeed to existing dispensaries.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

The era of the super bug is upon us, and Achaogen, Inc. (NASDAQ: AKAO) has joined the fray against them. For close to one hundred years, antibiotics have lowered the prevalence and severity of infectious diseases. Increasingly, though, it is becoming apparent that the bacterial world is fighting back. Infections of the urinary tract (UTI) and others such as acne, bronchitis and streptococcal pharyngitis (strep throat) are becoming more resistant to the antibiotics that are most commonly prescribed to treat them.

And this threat is compounded by the rise of the super bug, strains of bacteria that have already evolved defenses against a range of antibiotics. However, Achaogen is close to launching a new line of attack against these pathogens. Two phase III trials for its lead product candidate are currently in progress, and top-line results from both are expected in the first quarter of 2017.

Up until the 1930s, we were at the mercy of bacterial infections. Indeed, it was only about half a century before, in 1876, when German physician Robert Koch, in identifying the causes of anthrax, cholera and tuberculosis, showed that bacteria caused disease. In 1928, Dr. Alexander Fleming made the astounding discovery that the penicillium mold inhibited the growth of bacteria, and the penicillin extracted there from set a new paradigm for twentieth-century medical science. A PBS story (http://dtn.fm/Yl2DQ) gives some idea of its success:

“In the war, penicillin proved its mettle. Throughout history, the major killer in wars had been infection rather than battle injuries. In World War I, the death rate from bacterial pneumonia was 18 percent; in World War II, it fell, to less than 1 percent.”

Dr. Fleming was awarded the Nobel Prize in 1945, and, in his acceptance speech, he issued a prescient warning that the improper use of penicillin might eventually make it ineffective. If the drug could ‘be bought by anyone in the shops, then there is the danger that the ignorant man may easily under dose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant.’ Unfortunately, this prophesy has come true. Not only for penicillin, but for a wide range of other antibiotics, effectiveness today is markedly down from previous decades.

These dangers are exacerbated by a range of super bugs that are multi-drug resistant (MDR) and include carbapenem-resistant Enterobacteriaceae (CRE). Generally, healthy people in their normal environments do not contract CRE infections. Such maladies arise in hospitals, nursing homes, and other health care settings. It is for such malaises that Plazomicin is being developed. The drug will be used to treat serious bacterial infections due to MDR Enterobacteriaceae, including CRE.

It is currently being evaluated in two phase III clinical trials. For the first, designated EPIC (Evaluating Plazomicin in cUTI), Achaogen completed enrollment ahead of schedule in September with 609 patients. Top-line results are expected in the first quarter of 2017. The EPIC study is intended to serve as a single pivotal trial supporting a New Drug Application (NDA) for Plazomicin in the United States in the second half of 2017.

The second CARE (Combating Antibiotic Resistant Enterobacteriaceae) Phase III trial is for patients with serious bacterial infections due to CRE. Due to rapid completion of enrollment of the EPIC trial, Achaogen closed enrollment in the CARE trial with 69 patients and expects to announce top-line data from this trial early in the first quarter of 2017 as well. Results from CARE will be submitted with the NDA.

The FDA has granted Qualified Infectious Disease Product (QIDP) designation to Plazomicin, and development and regulatory review of its use to treat serious and life-threatening CRE infections has been given Fast Track status. The plazomicin program is partially funded by up to $103.8 million from the Biomedical Advanced Research and Development Authority (BARDA).

A report (http://dtn.fm/GKWi3) from Aegis Capital Corp. has set a target PPS of $10.00 for Achaogen. The company’s stock, under the symbol AKAO, is currently trading on the NASDAQ at under $5.00.

For more information, please visit www.achaogen.com

The alternative lodging rental market is maturing quickly, being one of the fastest growing verticals in the travel industry over the last few years. Already believed to be worth more than $100 billion worldwide, the sector continues to expand rapidly as more and more vacation rentals companies are joining the game alongside the now-famous HomeAway, Booking.com and Airbnb. Monaker Group, Inc. (OTCQB: MKGI), a technology-driven travel group that offers comprehensive tourism solutions and personalized tours, already maintains an important presence in the alternative lodging market, with a portfolio of more than one million rental units available.

The vacation rental market began expanding more quickly in the Internet era, starting with booking site VRBO, which was set up back in 1996 by a Colorado couple. The business was acquired by HomeAway in 2006 and became the dominant vacation rental listings hub. In 2015, HomeAway was purchased by Expedia (NASDAQ: EXPE) for $3.9 billion, a move that consolidated Expedia’s position as one of the largest online travel agents (OTA) operating at the moment. According to Expedia CEO Dara Khosrowshahi, the alternative lodging rental segment has become a major part of Expedia’s business, now having more than one million bookable listings available. The number continues to grow at a fast rate of over 20 percent, Khosrowshahi said.

Another major OTA, Priceline (NASDAQ: PCLN) occupies a good portion of the vacation rentals market through Booking.com listings. Booking.com now has about half a million instantly bookable vacation rental properties, which is almost 40 percent higher than in 2015. The approximately 1 million total properties listed on the website make for approximately 23.7 million bookable rooms, 7.3 million of which are in apartments, homes or villas, while the rest are in traditional hotels.

Capitalizing on a global trend of tourists looking for more personalized experiences wherever they travel, the vacation rental market is expected to grow significantly over the next few years, likely reaching $170 billion by 2019. Most of this growth is owed to Europe and the U.S., where the alternative lodging model is highly popular, according to a Research and Markets report (http://dtn.fm/mUT1g). Approximately 24 percent of travelers have opted for alternative lodging during the past two years, while roughly 47 percent are interested in staying at a vacation rental unit in the near future. In the U.S. in 2015, one in three tourists stayed in a private accommodation, which marks a significant change from 2011, when only one in ten Americans used alternative lodging.

With a portfolio of more than 1.1 million alternative lodging rental units available under its NextTrip Resorts platform, and currently in the process of adding more than 200,000 timeshare and resort units by the end of the year, Monaker Group is poised to establish a growing presence in the global vacation rentals market. The group owns several travel-related businesses, but its flagship is undoubtedly NextTrip.com, which allows tourists to plan their trips to the smallest details by offering them access to a wealth of alternative lodging options such as vacation home rentals, resort residences and unused timeshare inventory, all alongside a wide range of hotels, tours, rental cars, airlines, concierge services and more. The platform, launched in February 2016, has grown exponentially, being the first and only real-time booking engine that combines various booking options to meet tourists’ every need.

To further support the vacation rental market, Monaker Group this summer launched a Premium Service for alternative lodging owners, aimed at helping them compete against major travel industry suppliers, including hotels, car rental companies and airlines. The service offers various tools and features that will give homeowners real-time booking capabilities, the ability to update property pricing daily so as to better reflect the market conditions, and other benefits.

For more information, visit www.MonakerGroup.com

Let us hear your thoughts: Monaker Group, Inc. Message Board

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on developing and delivering biased ligands to discover the next generation of GPCR targeted medicine. The company is focused on three product candidates:

• Oliceridine, for moderate to severe acute pain;
• TRV734, an oral use medicine for people in moderate, severe acute, and chronic pain;
• and TRV250, for those suffering from migraines.

On November 7, 2016, Aegis Capital Corp. (http://dtn.fm/bB9sC) initiated coverage on Trevena, Inc., offering the company a ‘Buy’ rating with a target price of $14. This rating was released soon after the company reported its third quarter 2016 financial results alongside a corporate update. In the press release, CEO Maxine Gowen reported important progress for the quarter ending September 30, 2016.

According to Trevena’s third quarter report, top-line data from its APOLLO-1 and APOLLO-2 phase III efficacy trials of Oliceridine is on track for release in the first quarter of 2017, and the patient enrollment remains on track in the ETHENA multi-procedure safety study of Oliceridine to support an NDA filing in 2H 2017. Trevena, Inc. also announced that its TRV250 program is on track for IND submission this year.

The company has reported continued engagement at pain medicine conferences, and has hosted an investor webcast featuring presentations on acute pain management by leading clinicians.

Out of the seven analysts who have covered Trevena this year, six rated the company at ‘Buy’ and one at ‘Hold’. In the first weeks of November, Trevena has reported a stock price increase of roughly 50 percent to $5.75 per share as of November 11, an increase of $1.94 per share from its November 3 PPS.

For more information, visit the company’s website at www.trevena.com

Last month, Celldex Therapeutics, Inc. (NASDAQ: CLDX), a company in the business of developing targeted therapeutics for those suffering from devastating diseases for which current treatments are inadequate, found positive results from its phase II study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory. The study showed that patients experienced a confirmed response, with 52% of patients experiencing tumor shrinkage. In addition, by close of market on November 8, 2016, Celldex stock was up significantly as investors reacted to the company’s third quarter earnings report, which surpassed estimates for revenue and EPS. CLDX’s stock rose by nearly 15% to close at $3.78 on 9.01 million shares, more than four times the company’s average.

Aside from its recent growth, Celldex announced the acquisition of Kolltan Pharmaceuticals, Inc. on November 1. Kolltan is a privately owned clinical-stage company that develops new antibody-based drugs and is worth $62.5 million in stock. “Celldex believes Kolltan’s clinical candidates and preclinical platform are highly compatible with the Company’s scientific approach and can be developed independently and in combination with Celldex’s existing product candidates,” according to a statement shared on the Scibility Media website (http://dtn.fm/aD3xZ).

On November 7, Aegis Capital Corp. (http://dtn.fm/bXxJ5) initiated coverage on Celldex Therapeutics, Inc., giving the company a ‘Buy’ rating and a target price of $10. In addition, as of November 8, 2016, ClosingBell Active Analyst Ratings (http://dtn.fm/0W6w6) gave CLDX an average stock rating of 3.6 on a one to five scale, with five denoting ‘Buy’ and one indicating ‘Sell’. The numbers above are predicted to allow Celldex Therapeutics, Inc. to fund its operations through 2018.

For more information, visit the company’s website at www.celldex.com

Major Depressive Disorder (MDD) afflicts about 15 million Americans and is the leading cause of disability in the U.S. for those aged 15-44, according to the National Institute of Mental Health. Although experiencing the blues is part of the human condition, MDD is more than just the sadness that accompanies misfortune. MDD is a chronic feeling of enervation, loss of interest in activities, pessimism and hopelessness. At one time regarded as caused by supernatural forces, today, modern medical science generally attributes depression to chemical imbalances in the brain. However, with its small-molecule benzylpiperazine-aminopyridine drug NSI-189, Neuralstem, Inc. (NASDAQ: CUR) has evolved a new approach to lifting the blues.

NSI-189 was developed as a result of the research, undertaken by Neuralstem, into neural stem cell lines from the human hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. In a process referred to as neurogenesis, NSI-189 was shown to stimulate the generation of new neurons in vitro and in animal models. In phase Ib human clinical trials for MDD, NSI-189 demonstrated ‘clinically meaningful’ improvement across all depressive and cognitive measures.

This approach based on neurogenesis is a novel one. Current medications for depression generally attempt to modulate levels of different chemicals (neurotransmitters) in the brain. The most common type of such treatments is thought to be selective serotonin reuptake inhibitors (SSRIs).

In addition to the brain chemistry factors that cause depression, modern scholarship has uncovered a link between depression and the physiology of the brain. Those who suffer from chronic depression display reduced hippocampal volume. The healthy hippocampus, however, is a rich source of neural stem cells, from which new neurons are generated, making vital new connections throughout life. Neuralstem believes that stimulating the generation of new neurons in the hippocampus could potentially address the pathology of the depression itself.

Phase Ia trials, testing NSI-189 for use against MDD, kicked off in February 2011 and ended in October 2011. Healthy volunteers, unafflicted by depression, were tested with escalating single administration doses of NSI-189. Later, a similar trial was conducted for depression patients. In phase Ib, which commenced in June 2012 and ended in the fourth quarter of 2013, the safety of escalating doses of NSI-189 for 28 daily administrations in 24 patients suffering from MDD was tested.

At present, enrollment for a phase II trial has commenced. The trial, which is already 50 percent enrolled, is expected to yield top line results in the second half of 2017.

NSI-189 has had a colorful history. This feature in Bethesda magazine (http://dtn.fm/aRw8k) claims that NSI-189 stems from efforts by the Defense Advanced Research Projects Agency (DARPA), most famously home to the genesis of the internet, to cultivate ‘a “super soldier” who could stay awake and alert for a week at a time’. The contract was later cancelled and Neuralstem turned its attention to developing a remedy for the cell damage that can occur in the sleep-deprived hippocampus.

Neuralstem has the resources to expedite the clinical trial process. Through a recent agreement with the Tianjin Pharmaceutical Holding Group, the company has secured $20 million for completion of the phase II trial. This supplements the $11.1 million in cash on the balance sheet at the end of 2Q16.

In a report by Aegis Capital Corp. (http://dtn.fm/cZW0X), Neuralstem stock has been given a price target of $2.25. The share price on November 7 was $0.23. It seems that NSI-189 is lifting more than the blues.

For more information, visit www.neuralstem.com

Before the opening bell, Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) announced its financial and operational results for the third quarter of 2016, including a review of the October acquisition of MediGain, LLC and subsidiary Millennium Practice Management, LLC, which was the company’s largest acquisition to date. Notably, MTBC’s revenues for the three-month period were $5.3 million, up from $5.2 million in the previous quarter. The company also achieved its fourth consecutive quarter of positive adjusted EBITDA, reporting $130,000 for the third quarter and $209,000 year-to-date.

“We are pleased to announce another quarter of quarter-over-quarter revenue growth,” Mahmud Haq, chairman and chief executive officer of MTBC, stated in this morning’s news release. “Even though we continue to report a GAAP net loss, which is largely a result of non-cash amortization and depreciation expense, we are proud to report four consecutive quarters of positive adjusted EBITDA.”

Perhaps MTBC’s most significant achievement in the third quarter, the acquisition of Texas-based medical billing company MediGain, LLC, including substantially all of its assets and its subsidiary, positioned the company to build on its recent financial momentum moving forward. In total, the accounts in good standing acquired through this transaction have annual revenues in excess of $10 million. At a purchase price of just $7 million, the MediGain acquisition is expected to be accretive to MTBC shareholders in 2017, as incremental profits are expected to greatly exceed cost of capital. The acquisition also expanded MTBC’s global workforce, adding experienced team members in North America, as well as talented, cost-effective workforces in Asia.

“The successful closing of this transaction has positioned MTBC to experience exponential growth through access to new, untapped markets,” Haq continued. “In turn, we expect to expand our client base and deliver significant revenue growth in 2017.”

MTBC also reiterated plans for an upcoming offering of additional shares of its non-convertible Series A Preferred Stock in this morning’s update. The company is currently preparing to file a registration statement to sell 400,000 additional shares of its 11 percent Series A Cumulative Redeemable Perpetual Non-Convertible Preferred Stock at a price of $25 per share. If all of the shares are sold, the offering will generate roughly $9 million, of which $5 million will be used for the remaining payments related to the MediGain acquisition. This offering is not dilutive to shareholders and is expected to play a key role in positioning MTBC for forward growth.

Following this morning’s release, MTBC management hosted a conference call to discuss the results. An audio webcast of the call will be made available to the investment community on the company’s investor relations website at http://ir.mtbc.com.

For more information, visit www.mtbc.com, and see the company’s fact sheet at http://ir.mtbc.com/events.cfm.

It is no secret that the United States is going through some serious changes when it comes to marijuana. In the recent election, several states approved the legalization of marijuana for recreational purposes, with other states voting to approve medical marijuana initiatives. With Donald Trump winning the presidential election, it brings forward the question: how will this new presidency affect the marijuana industry in the U.S.?

Prior to the election, Alicia Wallace from the Cannabist (http://dtn.fm/8zKZ3) was able to share the four leading presidential candidates’ views on marijuana, including Trump’s. While the leading third-party candidates supported the legalization of marijuana, the Democratic and Republican party candidates did not seem as convinced, although neither took a particularly strong public stance on the matter.

While Trump showed strong views in favor of the legalization of all drugs back in 1990, they have been modified. In his more recent interview, Trump backed the use of medical marijuana, though he believes recreational use should be up to the states.

Although there has been talk of New Jersey Governor Chris Christie, who is not in favor of the legalization of marijuana, being a contender for the post of Attorney General, the marijuana industry does not yet seem to be worried. During an interview with television reporter Brandon Rittiman, Trump stood by his view of it being ‘up to the states’.

As a result, Singlepoint, Inc. (OTC: SING) subsidiary SingleSeed, a cannabis focused company established a few years ago to offer payment processing services to dispensaries, aims to capitalize on its current status within the marijuana industry while expanding to additional states.

By the end of this year, the size of the legal marijuana industry in the U.S. is projected to grow to $7.1 billion, according to a report by New Frontier and ArcView Market Research (http://dtn.fm/vE0s3). This represents a 26% jump from 2015, which is said to be largely due to expected adult recreational sales. States which have legalized marijuana are seeing a growth in what people are calling “green” taxes. Colorado is a prime example of how the legalization of marijuana can contribute to the financial status of each state, with revenue in “green” taxes of $70 million between 2014 and 2015.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

A research report (http://dtn.fm/w6uT3) issued earlier this week by Aegis Capital Corp. shows that Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR) has lived up to its promise since 2004, when it received startup funding from the Army under the Small Business Technology Transfer (STTR) program. Since then the company has been working on the development of new production technologies for humanized antibodies. Now it is close to making the fruits of that research available for the treatment of migraine, inflammatory diseases and autoimmune diseases with its lead product candidate, ALD403. Results of ongoing clinical trials are quite promising.

Trials of ALD403 go by the acronym “Promise”, which stands for PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy. These clinical trials are taking two paths: Promise 1 for the treatment of frequent episodic migraine (FEM) and Promise 2 for the treatment of chronic migraine (CM).

Phase I clinical trials of ALD403 kicked off in May 2012 for the treatment of migraine headaches. In March 2013, in what is now Promise 1, the first patients were dosed with ALD403 in phase II proof-of-concept clinical trials for the treatment of FEM. In October 2015, pivotal trials of ALD403 for FEM were commenced.

Following on from the initial studies on ALD403, phase IIb clinical trials were initiated in November 2014 for the treatment of CM (Promise 2). In March 2016, positive top line data was announced from the Promise 2 phase IIb study in patients with chronic migraine.

Now, Alder is moving ALD403 into phase III trials for both Promise 1 and Promise 2. For Promise 1, the pivotal trials are expected to report results in the first half of 2017, while results for Promise 2 should be ready about one year later, in the first half of 2018.

Migraine is a neurological disorder that is more prevalent than is commonly presumed. According to the Migraine Research Foundation (MRF), the condition affects about 38 million men, women and children, i.e. about 12 percent of the U.S. population. Worldwide, the illness is the third most prevalent and affects some one billion people. The condition is characterized by intense or throbbing pain in the head, commonly accompanied by nausea, vomiting and high sensitivity to light and sound. Over time, patients may be subject to an increasing frequency and severity of migraine attacks, potentially leading to significant disability. The MRF estimates that U.S. employers lose more than $13 billion each year as a result of 113 million lost work days due to migraine.

Currently approved medications for migraine include beta blockers (such as propranolol), topiramate, sodium valproate and botulinum toxin, or Botox. These generally lead to a range of side effects, including cognitive impairment, nausea, fatigue and sleep disturbance. As a result, only about 12 percent of adults with frequent episodic or chronic migraine take preventive medications, according to the U.S. Agency for Healthcare Research and Quality reports. Alder believes this creates a significant unmet medical need for new treatments with improved safety and efficacy that can either prevent migraines completely or reduce the frequency to a level where patients can find adequate relief from existing abortive medications.

For more information, visit www.alderbio.com

Likely the fastest growing cloud-based brokerage in the United States, eXp Realty recently announced that it has passed the 2,000-agent mark as more and more real estate professionals are choosing to join its ranks every day. A subsidiary of eXp World Holdings, Inc. (OTCQB: EXPI), eXp Realty announced that it expanded its agent base to more than 2,000 members in a Twitter post a few days ago.

The Agent-Owned Cloud Brokerage™ reported having a total of 2014 agents at the end of October, and since then, dozens of new members have joined. This makes it very likely that the company will reach and even surpass its target of having 2,200 agents by the end of the year. In addition to the individual real estate agents that joined the brokerage over the last few days, several realty firms have also entered its ranks. The most recent addition is Arkansas’s number two realty firm, Burch & Co. Real Estate, which transitioned its entire team of 17 brokers and agents to eXp Realty. Before them, the Agent-Owned Cloud Brokerage™ was joined by leading Baton Rouge, Louisiana, firm Darren James Real Estate Experts; one of the top realty teams in California – Sacramento’s Brent Gove Team; and South Texas’s top international luxury agent, Miguel Herrera.

This accelerated growth is largely due to the business model proposed by eXp Realty, a model that has been continuously pushing the brokerage further and acted as the driving force behind its continued growth and that of its parent company, EXPI. eXp Realty is, first of all, a brokerage of the future, embracing the latest technologies and virtual and augmented reality advancements to create a tight-knit community of real estate professionals covering 41 states, the District of Columbia and Alberta, Canada. Its use of virtual reality and cloud-based platforms reflects a growing trend in the real estate market that’s expected to reach new heights in 2017, according to the annual PwC report ‘Emerging Trends in Real Estate®’ (http://dtn.fm/dsuI9). The analysis puts emphasis on the increased quality of service that augmented reality can bring and notes that experts expect up to $2.6 billion in real estate VR/AR applications by 2025.

As a fully cloud-based brokerage, eXp Realty conducts all its operations through a virtual reality platform, from agent training to lead generation, leadership meetings, exchanges of ideas and experience, IT services and many more. In addition to helping agents and brokers stay connected 24/7 from the comfort of their own homes, this model also eliminates all the expenses traditionally associated with owning and running a brick-and-mortar office, so brokerage members are able to provide more efficient services to their consumers and increase their own profit without spending too much out of pocket. Another attractive feature of the eXp Realty model is that it gives its members the opportunity to become owners through lucrative revenue sharing programs and by enabling them to become shareholders in exchange for their contributions to the company’s growth and development.

For more information, visit the company’s website at www.eXpWorldHoldings.com

Let us hear your thoughts: eXp World Holdings, Inc. Message Board